公开(公告)号：US20230045357A1

公开(公告)日：2023-02-09

申请号：US17861809

申请日：2022-07-11

申请人： Université de Montréal ,  Bristol-Myers Squibb Company

发明人： Eldon Scott PRIESTLEY ,  Samuel Kaye REZNIK ,  Edward H. RUEDIGER ,  James R. GILLARD ,  Oz Scott HALPERN ,  Wen JIANG ,  Jeremy RICHTER ,  Rejean RUEL ,  Sasmita TRIPATHY ,  Wu YANG ,  Xiaojun ZHANG

IPC分类号： C07D401/14 ,  C07D401/10 ,  C07D235/26 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D257/04 ,  C07D417/14 ,  C07D405/14 ,  C07D233/90 ,  C07D498/10 ,  C07D413/14 ,  A61P9/04 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  C07D239/20 ,  C07D271/07

摘要： The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

公开(公告)号：US20190202808A1

公开(公告)日：2019-07-04

申请号：US16311835

申请日：2017-06-28

申请人： Universite de Montreal ,  Bristol-Myers Squibb Company

发明人： Eldon Scott PRIESTLEY ,  Samuel Kaye REZNIK ,  Edward H. RUEDIGER ,  James R. GILLARD ,  Oz Scott HALPERN ,  Wen JIANG ,  Jeremy RICHTER ,  Rejean RUEL ,  Sasmita TRIPATHY ,  Wu YANG ,  Xiaojun ZHANG

IPC分类号： C07D401/14 ,  C07D401/10 ,  C07D403/14 ,  C07D257/04 ,  C07D403/10 ,  C07D413/10 ,  C07D239/20 ,  C07D235/26 ,  C07D271/07 ,  C07D471/04 ,  A61K31/437 ,  A61K31/41 ,  A61K31/4439 ,  A61K31/4245 ,  A61K31/497 ,  A61K31/4709 ,  A61K31/427 ,  A61K31/501 ,  A61P9/04

CPC分类号： C07D401/14 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P9/04 ,  C07D233/90 ,  C07D235/26 ,  C07D239/20 ,  C07D257/04 ,  C07D271/07 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/10

摘要： The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.